NCT00554502已完成3 期
Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 148
- 试验地点
- 34
- 主要终点
- Patients reaching full clinical remission of their disease
研究概览
简要总结
- Evaluation of the efficacy of an immunosuppressive therapy added to a comprehensive supportive therapy to induce a clinical remission in patients at risk for progressive IgAN
- Investigation of differences between the treatments regarding the number of patients loosing more than 15 ml/min of GFR.
详细描述
The best treatment of glomerular diseases of the kidney is currently not well defined. This study aims to answer if in patients with IgA nephropathy, the most common type of glomerulonephritis an immunosuppressive treatment (with the use of steroids and chemotherapy) added to a supportive treatment is more effective than a supportive treatment alone (with the use of drugs lowering the blood pressure and the urinary protein loss).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients from 18-70 years with histologically proven primary IgAN with typical mesangioproliferative features. Diagnosis has to be made by a neuropathologist.
- •Proteinuria above 0.75 g/day within 12 weeks prior to or at the first visit in the run-in phase (month -6)and presence of at least one further risk factor for the development of end stage renal disease
- •arterial hypertension, defined as ambulatory blood pressure >140/90 mm Hg or the use of antihypertensive medication or
- •impaired renal function, defined as creatinine clearance or estimated GFR <90 ml/min.
排除标准
- •Known allergy or intolerance to study medication (except in case of ACE-inhibitor, in which case a change to an angiotensin receptor blocker is possible).
- •Women who are pregnant or breastfeeding and women without sufficient contraception.
- •Any prior immunosuppressive therapy.
- •Variants of primary IgAN (e.g. rapidly progressive IgAN with crescents in >50% of glomeruli or minimal change GN with glomerular IgA deposits).
- •Significant liver dysfunction (more than three fold increased GPT compared to norm)
- •Contraindication for immunosuppressive therapy, like
- •acute or chronic infectious disease incl. hepatitis and HIV positive patients
- •any malignancy
- •leukocytopenia, thrombocytopenia or known allergy against prednisolone, cyclophosphamide or azathioprine
- •active intestinal bleeding, active gastric or duodenal ulcer
- •Need of permanent immunosuppression, (e.g. transplanted patients, steroid-dependent inflammatory diseases)
- •Secondary IgAN or diseases associated with glomerular deposits of IgA.
- •Additional other chronic renal disease.
- •Creatinine clearance below 30 ml/min (mean of 3 measurements).
- •Alcohol or drug abuse
- •Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- •Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
- •Participation in a parallel clinical trial or participation in another clinical trial within the last 3 months.
- •Subjects who are in any state of dependency to the sponsor or the investigators.
- •Employees of the sponsor or the investigators.
- •Subjects who have been committed to an institution by legal or regulatory order.
研究组 & 干预措施
B
Active Comparator
干预措施: supportive and immunosuppressive therapy (Drug)
结局指标
主要结局
Patients reaching full clinical remission of their disease
时间窗: at the end of the 3 year study period.
GFR loss of 15 ml/min or higher from baseline GFR
时间窗: at the end of the 3 year study period
次要结局
- -Onset of end stage renal disease.(at the end of the 3 years study period)
- Mean annual change in one over serum creatinine concentration(at the end of the 3 years study period)
- Proteinuria at 12 and 36 months(12 and 36 months)
- Disappearance of microhematuria(at the end of the 3 years study period)
- GFR loss >=30 ml/min from baseline GFR(at the end of the 3 year study period)
- -Absolute GFR-change.(at the end of the 3 years study period)
研究者
研究点 (34)
Loading locations...
相似试验
进行中（未招募）
不适用
Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgAEUCTR2007-000871-41-DERWTH Aachen148
已完成
不适用
Study of combination immunosuppressive therapy in primary sclerosing cholangitis - A multicenter study for combination immunosuppressive therapy with mizoribine and azathioprinePrimary sclerosing cholangitisJPRN-UMIN000029482Osaka General Medical Center6
已完成
不适用
Combined therapy with immune-suppressive drug in children with immunoglobulin resistant Kawasaki diseaseKawasaki diseaseJPRN-UMIN000032096Dokkyo medical university52
已完成
4 期
Once-a-day Immunosuppression(CISECON_a_day)Chronic Renal DiseaseNCT01964014Ajou University School of Medicine160
Unknown
3 期
CZECH-ICIT (CZECH Inflammatory Cardiomyopathy Immunosuppression Trial)Inflammatory CardiomyopathyNCT01877746St. Anne's University Hospital Brno, Czech Republic234